<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-230X-1-6.anc" start="8361" end="8365" sStart="-1" offset="0" sid="null" wn="3" wnkey="time%1:28:00::" annotator="elstickles" text="That is, &lt;b&gt;time&lt;/b&gt; on therapy was felt to be associated with a 53% reduction from good health." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-230X-1-6.anc" start="8361" end="8365" sStart="null" offset="0" sid="null" wn="3" wnkey="time%1:28:00::" annotator="carichter" text="That is, &lt;b&gt;time&lt;/b&gt; on therapy was felt to be associated with a 53% reduction from good health." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-230X-1-6.anc" start="11450" end="11456" sStart="null" offset="0" sid="null" wn="10" wnkey="show%2:32:03::" annotator="elstickles" text="Further &lt;b&gt;work&lt;/b&gt; is needed to help physicians to understand their patients' views on hepatitis C. A recent study &lt;b&gt;showed&lt;/b&gt; that persons with hepatitis C preferred to expedite periods of poor health, implying that they may be more likely to proceed with antiviral therapy and its attendant side effects than to delay treatment [ 19 ] . In contrast, the physicians in the current survey had a relatively high threshold for recommending treatment, which would lead them to postpone therapy in the majority of cases." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-230X-1-6.anc" start="11450" end="11456" sStart="null" offset="0" sid="null" wn="2" wnkey="show%2:31:00::" annotator="carichter" text="Further &lt;b&gt;work&lt;/b&gt; is needed to help physicians to understand their patients' views on hepatitis C. A recent study &lt;b&gt;showed&lt;/b&gt; that persons with hepatitis C preferred to expedite periods of poor health, implying that they may be more likely to proceed with antiviral therapy and its attendant side effects than to delay treatment [ 19 ] . In contrast, the physicians in the current survey had a relatively high threshold for recommending treatment, which would lead them to postpone therapy in the majority of cases." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="9345" end="9350" sStart="null" offset="65" sid="r11.refer.v.0243" wn="4" wnkey="refer%2:38:00::" annotator="adelpriore" text="A survey of primary care physicians showed that only 62% refer anti-HCV positive patients with abnormal transaminase levels to sub-specialists [ 17 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="9009" end="9021" sStart="null" offset="257" sid="null" wn="1" wnkey="recommend%2:32:01::" annotator="vebatchelder" text="The 60% threshold far exceeds the 30% sustained response rate to interferon and ribavirin therapy reported for patients with hepatitis C genotype 1 infection [ 7 8 ] . In fact, only 13% of physicians reported a threshold for recommending therapy of 30% or less." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="13050" end="13062" sStart="null" offset="133" sid="r11.recommend.v.0445" wn="1" wnkey="recommend%2:32:01::" annotator="vebatchelder" text="Physicians provided particularly low preference values for side effects of antiviral therapy and high thresholds for recommending treatment." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="8704" end="8716" sStart="null" offset="97" sid="r11.recommend.v.0442" wn="1" wnkey="recommend%2:32:01::" annotator="vebatchelder" text="On average, physicians indicated that they would require a 60% sustained response before recommending therapy to their patients." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="4184" end="4193" sStart="null" offset="99" sid="r11.recommend.v.0439" wn="1" wnkey="recommend%2:32:01::" annotator="vebatchelder" text="That is, the sustained virologic response rate that they would require before they would recommend treatment to their patients." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="9009" end="9021" sStart="null" offset="257" sid="null" wn="1" wnkey="recommend%2:32:01::" annotator="anfahmy" text="The 60% threshold far exceeds the 30% sustained response rate to interferon and ribavirin therapy reported for patients with hepatitis C genotype 1 infection [ 7 8 ] . In fact, only 13% of physicians reported a threshold for recommending therapy of 30% or less." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="13177" end="13189" sStart="null" offset="95" sid="r11.recommend.v.0446" wn="1" wnkey="recommend%2:32:01::" annotator="anfahmy" text="However, ratings of side effects were not significantly correlated with thresholds for recommending therapy, suggesting that additional factors effect physicians views about antiviral therapy." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="9009" end="9021" sStart="null" offset="257" sid="r11.recommend.v.0443" wn="1" wnkey="recommend%2:32:01::" annotator="anfahmy" text="The 60% threshold far exceeds the 30% sustained response rate to interferon and ribavirin therapy reported for patients with hepatitis C genotype 1 infection [ 7 8 ] . In fact, only 13% of physicians reported a threshold for recommending therapy of 30% or less." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="6138" end="6150" sStart="null" offset="229" sid="r11.recommend.v.0440" wn="1" wnkey="recommend%2:32:01::" annotator="anfahmy" text="After considering the HCV health states and the side effects of therapy, physicians indicated that they would require a median of a 60% sustained response rate (interquartile range 40%-80%) before recommending treatment." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="2028" end="2040" sStart="null" offset="419" sid="r11.recommend.v.0437" wn="1" wnkey="recommend%2:32:01::" annotator="anfahmy" text="Utility analysis provides a means to quantify preference values about disease states [ 13 14 ] . The aims of the study were: 1) to assess whether physicians could provide utilities for hepatitis C health state constructs using visual analog scales, 2) to quantify physicians' judgments about various hepatitis C health states, and 3) to assess physicians' thresholds for recommending treatment." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="9974" end="9983" sStart="null" offset="179" sid="r11.recommend.v.0068" wn="1" wnkey="recommend%2:32:01::" annotator="anfahmy" text="Our data show that a group of physicians, comprised largely of primary care providers, would require a high degree of benefit in terms of response rate to recommend therapy for HCV, which was not necessarily related to their perspectives on the harm associated with treatment side effects." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="11803" end="11815" sStart="null" offset="470" sid="r11.recommend.v.0053" wn="1" wnkey="recommend%2:32:01::" annotator="anfahmy" text="Further work is needed to help physicians to understand their patients' views on hepatitis C. A recent study showed that persons with hepatitis C preferred to expedite periods of poor health, implying that they may be more likely to proceed with antiviral therapy and its attendant side effects than to delay treatment [ 19 ] . In contrast, the physicians in the current survey had a relatively high threshold for recommending treatment, which would lead them to postpone therapy in the majority of cases." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="9009" end="9021" sStart="null" offset="257" sid="null" wn="1" wnkey="recommend%2:32:01::" annotator="adelpriore" text="The 60% threshold far exceeds the 30% sustained response rate to interferon and ribavirin therapy reported for patients with hepatitis C genotype 1 infection [ 7 8 ] . In fact, only 13% of physicians reported a threshold for recommending therapy of 30% or less." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="9602" end="9614" sStart="null" offset="138" sid="r11.recommend.v.0444" wn="1" wnkey="recommend%2:32:01::" annotator="adelpriore" text="The lack of a significant correlation between the respondents' ratings of treatment side effects and their thresholds for recommending treatment is surprising." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="6561" end="6573" sStart="null" offset="205" sid="r11.recommend.v.0441" wn="1" wnkey="recommend%2:32:01::" annotator="adelpriore" text="Health state utility values did not vary significantly with physicians' age, gender, race, specialty or whether they treated hepatitis C. Ratings of side effects and thresholds for recommending treatment were similar across the demographic variables." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="4043" end="4055" sStart="null" offset="73" sid="r11.recommend.v.0438" wn="1" wnkey="recommend%2:32:01::" annotator="adelpriore" text="Finally, participating physicians provided their threshold for recommending antiviral therapy." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="9974" end="9983" sStart="null" offset="179" sid="r11.recommend.v.0068" wn="1" wnkey="recommend%2:32:01::" annotator="adelpriore" text="Our data show that a group of physicians, comprised largely of primary care providers, would require a high degree of benefit in terms of response rate to recommend therapy for HCV, which was not necessarily related to their perspectives on the harm associated with treatment side effects." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="11803" end="11815" sStart="null" offset="470" sid="r11.recommend.v.0053" wn="1" wnkey="recommend%2:32:01::" annotator="adelpriore" text="Further work is needed to help physicians to understand their patients' views on hepatitis C. A recent study showed that persons with hepatitis C preferred to expedite periods of poor health, implying that they may be more likely to proceed with antiviral therapy and its attendant side effects than to delay treatment [ 19 ] . In contrast, the physicians in the current survey had a relatively high threshold for recommending treatment, which would lead them to postpone therapy in the majority of cases." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-230X-1-6.anc" start="9966" end="9970" sStart="null" offset="0" sid="null" wn="3" wnkey="rate%1:07:00::" annotator="cgozo" text="Our data show that a group of physicians, comprised largely of primary care providers, would require a high degree of benefit in terms of response &lt;b&gt;rate&lt;/b&gt; to recommend therapy for HCV, which was not necessarily related to their perspectives on the harm associated with treatment side effects." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-230X-1-6.anc" start="9966" end="9970" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="brubin" text="Our data show that a group of physicians, comprised largely of primary care providers, would require a high degree of benefit in terms of response &lt;b&gt;rate&lt;/b&gt; to recommend therapy for HCV, which was not necessarily related to their perspectives on the harm associated with treatment side effects." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="3551" end="3555" sStart="null" offset="193" sid="r8.life.n.0285" wn="4" wnkey="life%1:26:00::" annotator="veweser" text="Physicians rated hepatitis C health states using a visual analog scale where 0% represented death and 100% corresponded to life without hepatitis C. We designated life without hepatitis C as the highest preference value and assessed preferences for the health state hepatitis C with No Symptoms, No cirrhosis because the psychological impact of having a disease can effect health status in the absence of physical symptoms." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="7536" end="7540" sStart="null" offset="129" sid="r8.life.n.0555" wn="5" wnkey="life%1:28:00::" annotator="brubin" text="Even the presence of hepatitis C, without symptoms or cirrhosis (HS 1), was judged to carry a 12% decrement from life without HCV." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="5700" end="5704" sStart="null" offset="32" sid="r8.life.n.0411" wn="3" wnkey="life%1:26:02::" annotator="brubin" text="The median preference value for life with the side effects of antiviral therapy was 47% (interquartile range 23%-55%)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="9754" end="9761" sStart="null" offset="114" sid="r11.benefit.n.0551" wn="2" wnkey="benefit%1:07:00::" annotator="anfahmy" text="We would expect clinicians to make decisions that are consistent with their views on the harm and benefit of a particular therapy." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-230X-1-6.anc" start="3822" end="3829" sStart="null" offset="464" sid="r11.absence.n.0750" wn="1" wnkey="absence%1:26:00::" annotator="adelpriore" text="Physicians rated hepatitis C health states using a visual analog scale where 0% represented death and 100% corresponded to life without hepatitis C. We designated life without hepatitis C as the highest preference value and assessed preferences for the health state hepatitis C with No Symptoms, No cirrhosis because the psychological impact of having a disease can effect health status in the absence of physical symptoms." />
  </sentences>
</list>